Malignancies may initially present with muscle weakness and elevated muscle enzymes. Age and gender-specific cancer screening should be completed or updated in those with a myopathic process. 9,10 ...

argenx stock enters a catalyst week as ACR Convergence starts in Orlando on November 6. ALKIVIA data are scheduled for a late ...

argenx stock enters a key clinical week ahead of new ALKIVIA results in autoimmune myositis. The presentation is set for ...

Engineered three-dimensional muscle bundles grown from pediatric patients with juvenile dermatomyositis, immune-mediated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase ...

The ALKIVIA trial was a global, randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of autoimmune myositis across ...

The final diagnosis was autoimmune inflammatory myositis of the necrotizing myopathy subtype. Annabelle was treated with a loading dose of methylprednisolone sodium succinate (1 g intravenously daily ...

Argenx announced positive top-line results from its phase 3 trial of Vyvgart in autoimmune myositis, or IIM, with the study meeting its primary endpoint at week 52 in the combined patient population ...

Idiopathic inflammatory myopathies (IIM) are characterized by muscle weakness and immune-mediated muscle injury. Tumor necrosis factor (TNF) appears to be involved in the pathogenesis of IIM, ...